Deferral of MSMby Andrew I. Dayton, M.D., Ph. D.
- In November of 1998, FDA hosted a workshop on Donor Suitability.
- The highlights of this workshop were presented to the BPAC in December of 1998.
- Widespread adoption of NAT for HCV and HIV, providing, amongst other benefits, redundancy.
- Better understanding of blood bank error rates.